valneva se glp-1 receptor agonist weight management diabetes treatments Agonists: A Comprehensive Overview GLP-1 Receptor Agonists as Treatments

Di Muro, F

It is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (under the brand name Mounjaro) and chronic weight management in adults with obesity or overweight with weight-related comorbidities (under the brand name Zepbound)

[4] Rudnicka E, Suchta K, Grymowicz M, et al

Treatment is time-limited and must be delivered as part of a specialist multidisciplinary programme

If treating a specific injury, localized swelling begins to decrease

Patients with Renal Impairment In adult patients with type 2 diabetes mellitus with mild (eGFR: 60 to less than 90 mL/min/1.73 m2), moderate (eGFR: 30 to less than 60 mL/min/1.73 m2), and severe (eGFR: less than 30 mL/min/1.73 m2) renal impairment and patients on dialysis due to kidney failure, AUC of empagliflozin increased by approximately 18%, 20%, 66%, and 48%, respectively, compared to subjects with normal renal function